Long-Term Outcome After Chemoembolization and Embolization of Hepatic Metastatic Lesions from Neuroendocrine Tumors

• DOI: 10.2214/ajr.06.0933
• Publication Date: 2007-04-20T18:50:26Z
• Authors: Alexander S. Ho; Joel Picus; Michael D. Darcy; Benjamin Tan; Jennifer E. Gould; Thomas K. Pilgram; Daniel B. Brown
• Keywords: Hepatic artery embolization

Hepatic artery chemoembolization and hepatic embolization (HAE) are accepted treatments of patients with metastasis from neuroendocrine tumors. Long-term outcome data limited. We present our experience in the use treatment tumors.Forty-six carcinoid (n = 31) or islet cell 15) tumors were treated. Overall progression-free survival times starting first calculated. Potential factors affecting survival, including presence extrahepatic disease resection primary lesion, analyzed. Relief symptoms was subjectively determined for hormonal secretion.The 46 underwent 93 HAE sessions. The mean overall time entire group 1,273 +/- 185 days. (1,255 163 days) tumor (1,311 403 subgroups similar (p 0.66). (602 144 (501 107 also 0.72). without known 18; 1,571 291 trended toward significance compared that 26; 770 112 days; p 0.08). Resection 19 did not affect (resection 1,558 400 nonresection 1,000 179 0.44). Twenty 25 hormonally active had relief after one cycle treatment. 30-day mortality 4.3%.The among is approximately 3.5 years. approaches 1.5 an unresected should limit HAE.